Ayan Chatterjee, MD
Glaucoma Specialist · King Of Prussia, PANPI 1265845804
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,223 of the $16,973 with a category attached, or 72.0%. 20 manufacturers reported payments, led by Alcon at 37.0% of the total. 2025 is the largest year on record at $7,437, more than ten times the $717 reported in 2019.
Across 241 payments — averaging $70.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$6K
- Rxsight Inc$5K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Sight Sciences, Inc.$1K
- Ivantis, Inc$829
- Glaukos Corporation$543
- plus $2K from 14 others
What the payments were for
- Consulting fees$4,70828%
- Speaking & faculty fees$260%
- Food & beverage$12,22372%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 113 | $6,283 |
| Rxsight Inc | 14 | $4,789 |
| Johnson & Johnson Surgical Vision, Inc. | 19 | $1,280 |
| Sight Sciences, Inc. | 24 | $1,215 |
| Ivantis, Inc | 12 | $829 |
| Glaukos Corporation | 5 | $543 |
| Nova Eye, Inc. | 1 | $487 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $321 |
| AbbVie(2 entities) | 13 | $295 |
| Omeros Corporation | 3 | $219 |
| NEW World Medical,inc. | 4 | $191 |
| Aerie Pharmaceuticals, Inc. | 5 | $132 |
| Bausch & Lomb Americas Inc. | 7 | $116 |
| Harrow Eye, LLC | 4 | $87 |
| Sun Pharmaceutical Industries Inc. | 3 | $56 |
| Genentech USA, Inc. | 2 | $47 |
| Novartis | 2 | $27 |
| Amgen | 1 | $21 |
| Dompe US, Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$4,346
- RXSIGHT INJECTOR CARTRIDGE$4,346
- LIGHT ADJUSTABLE LENS (LAL)$4,346
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,346
- RXSIGHT INJECTOR HANDPIECE$4,346
- Clareon$2,558
- Tecnis IOL$887
- Hydrus Microstent$876
- OMNI(R) SURGICAL SYSTEM (US)$757
- Clareon PanOptix Pro$428
- CATALYS SYSTEM$382
- Rhopressa$230
- Rocklatan$230
- iStent infinite Trabecular Micro-Bypass System Model iS3$199
- Kahook Dual Blade$151
- Streamline Surgical System$151
- Ahmed Glaucoma Valve$151
- Tecnis Simplicity$147
- iStent inject W$128
- OMIDRIA$123
How this compares
Too few glaucoma specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 48 | $26,439 |
| LumiganBimatoprost | 46 | $21,424 |
| Prednisolone Acetate | 455 | $15,666 |
| VyzultaLatanoprostene Bunod | 14 | $10,277 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $9,350 |
| Latanoprost | 844 | $9,226 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $8,217 |
| Alphagan PBrimonidine Tartrate | 24 | $7,788 |
| RestasisCyclosporine | 12 | $7,174 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 58 | $6,361 |
| Brimonidine Tartrate | 235 | $5,921 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $5,565 |
| Ketorolac Tromethamine | 366 | $5,345 |
| Travoprost | 39 | $4,762 |
| Timolol Maleate | 337 | $3,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $295 | $44,603102 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $132 | $35,78869 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $116 | $10,27714 claims |
| AlconSimbrinza | $6,283 | $5,56525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in King Of Prussia
- Mehul NagarshethWyomissing$32K
- Abhishek NemaniWyomissing$10K
- Alex TheventhiranPhiladelphia$4K
- Andrew WilliamsPittsburgh$4K
- Zachary NadlerAbington$4K
- Tadhg SchempfSewickley$3K
- Moon Jeong LeePhiladelphia$3K
- Michael SmithWyomissing$3K
- Shelley MoLancaster$3K
- Monica ZhangPhiladelphia$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.